Spots Global Cancer Trial Database for ds stage ii multiple myeloma
Every month we try and update this database with for ds stage ii multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma | NCT00098475 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... | Dexamethasone Laboratory Biom... Lenalidomide Thalidomide | 18 Years - | National Cancer Institute (NCI) | |
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma | NCT00644228 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... | Bortezomib Dexamethasone Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) |